Hepatic resection for recurrent metastatic ovarian cancer

Am J Surg. 2008 Mar;195(3):370-3; discussion 373. doi: 10.1016/j.amjsurg.2007.12.012.

Abstract

Background: The role for liver resection in metastatic ovarian cancer has not been defined. The aim of the current study was to investigate the validity of hepatic resection as a treatment option in metastatic ovarian cancer.

Methods: Retrospective review of a single institution's experience of patients undergoing hepatic resection for metastatic ovarian cancer from 1998-2006.

Results: Ten patients underwent resection for metastatic ovarian cancer. Primary tumor type included serous cystadenocarcinoma (n = 8), granulosa cell (n = 1), and yolk sac (n = 1). Median disease-free interval was 48 months. Liver resections included trisegmentectomy (n = 4), lobectomy (n = 4), and bisegmentectomy(n = 1). Additional surgeries included diaphragm resection (n = 60), bowel resection, (n = 30), and adrenalectomy (n = 10). The median overall survival following liver resection was 33 months.

Conclusion: Liver resection for metastatic ovarian cancer is safe and is associated with long-term survival in some patients. Larger analysis may lead to the identification of prognostic factors associated with improved outcomes.

Publication types

  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Cystadenocarcinoma / secondary
  • Cystadenocarcinoma / surgery
  • Endodermal Sinus Tumor / secondary
  • Endodermal Sinus Tumor / surgery
  • Female
  • Granulosa Cell Tumor / secondary
  • Granulosa Cell Tumor / surgery
  • Hepatectomy*
  • Humans
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery*
  • Middle Aged
  • Neoplasm Recurrence, Local / surgery*
  • Ovarian Neoplasms / secondary
  • Ovarian Neoplasms / surgery*
  • Retrospective Studies